Scinovex
review Open AccessTop 1% cited

Implications of the Hybrid Epithelial/Mesenchymal Phenotype in Metastasis

Frontiers in Oncology · 2015 · Vol. 5 · pp. 155–155
Mohit Kumar Jolly

Abstract

Transitions between epithelial and mesenchymal phenotypes - the epithelial to -mesenchymal transition (EMT) and its reverse the mesenchymal to epithelial transition (MET) - are hallmarks of cancer metastasis. While transitioning between the epithelial and mesenchymal phenotypes, cells can also attain a hybrid epithelial/mesenchymal (E/M) (i.e., partial or intermediate EMT) phenotype. Cells in this phenotype have mixed epithelial (e.g., adhesion) and mesenchymal (e.g., migration) properties, thereby allowing them to move collectively as clusters. If these clusters reach the bloodstream intact, they can give rise to clusters of circulating tumor cells (CTCs), as have often been seen experimentally. Here, we review the operating principles of the core regulatory network for EMT/MET that acts as a "three-way" switch giving rise to three distinct phenotypes - E, M and hybrid E/M - and present a theoretical framework that can elucidate the role of many other players in regulating epithelial plasticity. Furthermore, we highlight recent studies on partial EMT and its association with drug resistance and tumor-initiating potential; and discuss how cell-cell communication between cells in a partial EMT phenotype can enable the formation of clusters of CTCs. These clusters can be more apoptosis-resistant and have more tumor-initiating potential than singly moving CTCs with a wholly mesenchymal (complete EMT) phenotype. Also, more such clusters can be formed under inflammatory conditions that are often generated by various therapies. Finally, we discuss the multiple advantages that the partial EMT or hybrid E/M phenotype have as compared to a complete EMT phenotype and argue that these collectively migrating cells are the primary "bad actors" of metastasis.

Cancer Cells and MetastasisHippo pathway signaling and YAP/TAZFOXO transcription factor regulationMesenchymal stem cellPhenotypeEpithelial–mesenchymal transitionMetastasisCancer researchBiologyCirculating tumor cellCell biologyCancerGene

Funding

  • National Science Foundation
  • Cancer Prevention and Research Institute of Texas
  • Rice University
  • Fundação de Amparo à Pesquisa do Estado de São Paulo
Citations
688
FWCI
26.73
field-weighted impact
References
242
Percentile
100%
vs. same field & year
Citations per year
Cited by
Tumor Budding: The Name is EMT. Partial EMT.
Journal of Clinical Medicine · 2016 · 487 citations
EMT Factors and Metabolic Pathways in Cancer
Frontiers in Oncology · 2020 · 355 citations
EMT: 2016
Cell · 2016 · 4,367 citations
Citation Network

How this paper connects to the literature. Drag to explore, click any node to open that paper.